These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1391037)

  • 1. The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes.
    Hum Gene Ther; 1992 Apr; 3(2):167-77. PubMed ID: 1391037
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombinant interleukin-2 alone, or with recombinant interleukin-2 and recombinant alpha interferon.
    Hum Gene Ther; 1992 Aug; 3(4):411-30. PubMed ID: 1326336
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin.
    Favrot MC; Philip T
    Hum Gene Ther; 1992 Oct; 3(5):533-42. PubMed ID: 1420452
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocytes in melanoma.
    Lee S; Margolin K
    Curr Oncol Rep; 2012 Oct; 14(5):468-74. PubMed ID: 22878966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma.
    Tessier MH; Pandolfino MC; Jotereau F; Boudart D; Litoux P; Dréno B
    Eur J Cancer; 1996 Apr; 32A(4):735-6. PubMed ID: 8695283
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 9. T cell triumph. Immunotherapy may have finally turned a corner.
    Martindale D
    Sci Am; 2003 Feb; 288(2):12-3. PubMed ID: 12561452
    [No Abstract]   [Full Text] [Related]  

  • 10. T cells take aim at cancer.
    Pardoll D
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15840-2. PubMed ID: 12461164
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of metastatic melanoma with interleukin-2].
    Chosidow O; Guillaume JC
    Ann Dermatol Venereol; 1992; 119(1):65-73. PubMed ID: 1373275
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunotherapy of malignant melanoma].
    Flageul B; Miclea JM; Bensussan A; Degos L
    Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
    [No Abstract]   [Full Text] [Related]  

  • 13. A major player "gets in the act".
    Dudley ME
    J Immunother; 2012 Oct; 35(8):595-7. PubMed ID: 22996364
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic therapy in disseminated melanoma.
    Rümke PH
    Semin Surg Oncol; 1992; 8(6):392-9. PubMed ID: 1279776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
    Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F
    Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
    Marincola FM; Venzon D; White D; Rubin JT; Lotze MT; Simonis TB; Balkissoon J; Rosenberg SA; Parkinson DR
    Cancer Res; 1992 Dec; 52(23):6561-6. PubMed ID: 1423301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
    Dréno B; Nguyen JM; Khammari A; Pandolfino MC; Tessier MH; Bercegeay S; Cassidanius A; Lemarre P; Billaudel S; Labarrière N; Jotereau F
    Cancer Immunol Immunother; 2002 Nov; 51(10):539-46. PubMed ID: 12384805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy of malignant melanoma.
    Oratz R; Bystryn JC
    Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study].
    Thiounn N; Mathiot C; Flam T; Tartour E; Peyret C; Joyeux I; Abecassis JP; Zerbib M; Fridman WH; Debré B
    J Urol (Paris); 1994; 100(4):185-8. PubMed ID: 7868930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.